Table 3.
Lung-cancer-specific RMST in males compared to females treated with curative or palliative intent and for different histologies.
| Stratification | N | Follow-up | Difference in RMST (months) | 95% confidence interval |
|---|---|---|---|---|
| Treatment intent | ||||
| Curative treatmenta,c | 409 | 5 years | -0.07 | -3.4, 3.2 |
| Palliative treatmentb,c | 804 | 2 years | -0.88 | -1.9, 0.16 |
| Histology | ||||
| Adenocarcinomad | 545 | 5 years | -1.0 | -2.9, 0.88 |
a
Surgery, stereotactic beam radiation therapy or chemoradiation with curative intent, ECOG 0–2 and histology confirmed lung cancer. RMST: restricted mean survival time.
b
Palliative chemotherapy, radiotherapy, chemoradiotherapy or supportive care only.
c
Adjusted for combined stage and treatment group, Eastern Cooperative Oncology Group Performance Status (ECOG PS), smoking, age, histology, EGFR/ALK/immunotherapy treatment and period.
d
Adjusted for the same as c except histology.